Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mitoxantrone + cytarabine + cyclophosphamide + etoposide + interferon alfa
- Development stage
- Phase 2
- Lead developer
- Memorial Sloan Kettering Cancer Center
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Intravenous, Subcutaneous
01
Overview
This combination chemotherapy and immunotherapy regimen was developed and studied by Memorial Sloan Kettering Cancer Center (MSKCC) for the treatment of chronic myelogenous leukemia (CML) in myeloid blast crisis. The regimen utilizes a multi-agent approach to overcome the aggressive nature of the blast phase. It consists of mitoxantrone (a DNA intercalator and topoisomerase II inhibitor), high-dose cytarabine (an antimetabolite that inhibits DNA polymerase), cyclophosphamide (an alkylating agent), and etoposide (a topoisomerase II inhibitor). These cytotoxic agents are followed by consolidation with interferon alfa, a biological response modifier that exerts antiproliferative and immunomodulatory effects. The intensive induction phase aims to achieve hematologic and cytogenetic remission, often as a bridge to further consolidation therapies such as stem cell transplantation.
- Other names
- Mitoxantrone, Cytarabine, Cyclophosphamide, Etoposide, and Interferon Alfa in CML Blast CrisisMitoxantrone and High-Dose Ara-C followed by Cyclophosphamide and Etoposide
02
Targets
DNADNA polymerase familyTOP2A (DNA topoisomerase II)IFNAR1 (Interferon alpha/beta receptor 1)IFNAR2 (Interferon alpha/beta receptor subunit 2)IFNAR (Immune system modulation via type I interferon receptor)
Beyond the preview
Go deeper on mitoxantrone + cytarabine + cyclophosphamide + etoposide + interferon alfa.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mitoxantrone + cytarabine + cyclophosphamide + etoposide + interferon alfa.